Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

MABS487 Anti-Modified Citrulline Antibody, clone C4

MABS487
100 µL  
Purchase on Sigma-Aldrich

Ofertas especiales

Descripción

Replacement Information

Ofertas especiales

Tabla espec. clave

Species ReactivityKey ApplicationsHostFormatAntibody Type
AWB, ELISAHuman RecombinantPurifiedMonoclonal Antibody
Description
Catalogue NumberMABS487
DescriptionAnti-Modified Citrulline Antibody, clone C4
Alternate Names
  • citrulline
  • modified citrulline
Background InformationCitrulline is thought to be an unincorporated amino acid that plays a part in intermediary metabolism. It is produced in the small intestine by enterocytes. Citrulline concentration in plasma and serum is thought to be a reliable and noninvasive biomarker of small intestine function and mass during disease. Citrulline has also been shown to play an important role in protein homeostasis. Modified citrulline is a chemically modified form of citrulline that is more immunogenic.
References
Product Information
FormatPurified
PresentationHuman recombinant monoclonal IgG1λ in buffer containing PBS with 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationThis Anti-Modified Citrulline Antibody is validated for use in Western blotting and ELISA for the detection of Modified Citrulline.
Key Applications
  • Western Blotting
  • ELISA
Application NotesWestern Blotting Analysis: A 1:1,000 dilution from a representative lot detected Modified Citrulline in 10 µg of treated HL-60 cell lysate, using Anti-Human secondary antibody.
ELISA Analysis: A representative lot detected Modified Citrulline in ELISA.
Biological Information
ImmunogenCitrulline-containing peptide modified with 2,3-butanedione monoxime and antipyrine.
CloneC4
ConcentrationPlease refer to lot specific datasheet.
HostHuman Recombinant
IsotypeIgG1λ
Species Reactivity
  • All
Antibody TypeMonoclonal Antibody
Purification MethodProtein A Purfied
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blotting in treated cornified human cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Modified Citrulline in 10 µg of treated cornified human cell lysate, using Anti-Human secondary antibody.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
MABS487 04055977158878

Documentation

Anti-Modified Citrulline Antibody, clone C4 Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Anti-Modified Citrulline Antibody, clone C4 Certificados de análisis

CargoNúmero de lote
Anti-Modified Citrulline, clone C4 3068537
Anti-Modified Citrulline, clone C4 - 3159551 3159551
Anti-Modified Citrulline, clone C4 - 3169851 3169851
Anti-Modified Citrulline, clone C4 - 3193848 3193848
Anti-Modified Citrulline, clone C4 - 3284333 3284333
Anti-Modified Citrulline, clone C4 - 3318418 3318418
Anti-Modified Citrulline, clone C4 - 3407336 3407336
Anti-Modified Citrulline, clone C4 - 3463633 3463633
Anti-Modified Citrulline, clone C4 - 3492223 3492223
Anti-Modified Citrulline, clone C4 - 3508396 3508396

Folleto

Cargo
NPI Flyer- Epigenetics and Nuclear Function Feature
New Products - Antibodies, Small Molecule, Inhibitors

Licencias necesarias e Información técnica

Cargo
White Paper: Further considerations of antibody validation and usage.